(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 552.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Inovio Pharmaceuticals's revenue in 2025 is $283,099.On average, 2 Wall Street analysts forecast INO's revenue for 2025 to be $4,951,049, with the lowest INO revenue forecast at $2,567,211, and the highest INO revenue forecast at $7,334,887. On average, 3 Wall Street analysts forecast INO's revenue for 2026 to be $639,602,164, with the lowest INO revenue forecast at $33,006,992, and the highest INO revenue forecast at $1,522,722,583.
In 2027, INO is forecast to generate $3,320,503,435 in revenue, with the lowest revenue forecast at $2,152,789,393 and the highest revenue forecast at $4,488,217,478.